Efficacy and Safety of Deucravacitinib in Moderate to SeverePlaque Psoriasis:A Meta-Analysis
OBJECTIVE To evaluate deucravacitinib in the moderate to severe plaque psoriasis with regard to efficacy and safety.METHODS The randomized controlled trials(RCTs)of the comparison between deucravacitinib and placebo in the treatment of moderate to severe plaque psoriasis in PubMed,Embase,the Cochrane Library,ClinicalTrials.gov,CBM,VIP,and WanFang databases were electronically searched before October 2022.After screening studies,the quality assessment of included studies was done with bias risk assessment tool provided by the Cochrane Reviews'Handbook 5.1.0,the scores of included studies was performed with modified JadadScale.RevMan 5.4 software was used for Meta-analysis.RESULTS Three studies were included in analysis,with a total of 1 953 patients.The results of Meta-analysis indicated thatstatistically significant decreased 75％in the psoriasis area and severity index reduction intrial grouppatients compared to baseline(PASI 75)[RR=5.36,95％CI(4.07,7.06),P＜0.000 01],astatic Physician's Global Assessment score of 0 or 1(sPGA 0/1)[RR=6.52,95％CI(4.75,8.95),P＜0.000 01],dermatology life quality index of 0 or 1(DLQI 0/1)[RR=4.10,95％CI(3.04,5.52),P＜0.000 01],PASI 90[RR=9.20,95％CI(5.53,15.32)P＜0.000 01]and PASI 100[RR=12.06,95％CI(4.73,30.72),P＜0.000 01]in deucravacitinib group as compared to control.The risk of the total adverse events with deucravacitinib were increased as compared to placebo[RR=1.15,95％CI(1.03,1.27),P=0.01],while no significant difference in serious adverse events and the most frequent adverse events.CONCLUSION Deucravacitinib is effective in the treatment of moderate to severe plaque psoriasis,and most of adverse events are mild and moderate.In addition,patiens show better compliance and tolerance.Deucravacitinib is expected to become a new drug for the clinical treatment of moderate to severe plaque psoriasis.
万方数据
维普
